IMMUNE RESPONSE CORP
10-Q, EX-27, 2000-08-14
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: IMMUNE RESPONSE CORP, 10-Q, EX-10.74, 2000-08-14
Next: BURNS INTERNATIONAL SERVICES CORP, 10-Q, 2000-08-14



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONDENSED CONSOLIDATED BALANCE SHEETS AND CONSOLIDATED STATEMENTS OF OPERATIONS
EXTRACTED FROM ITEM 1 OF FORM 10-Q FOR THE PERIOD ENDED JUNE 30, 2000 AND
YEAR-T0-DATE AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL
STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-31-2000
<PERIOD-END>                               JUN-30-2000
<CASH>                                           9,287
<SECURITIES>                                    15,947
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                25,696
<PP&E>                                          18,265
<DEPRECIATION>                                   9,106
<TOTAL-ASSETS>                                  40,294
<CURRENT-LIABILITIES>                            4,193
<BONDS>                                              0
                            9,767
                                          0
<COMMON>                                            68
<OTHER-SE>                                      21,477
<TOTAL-LIABILITY-AND-EQUITY>                    40,294
<SALES>                                              0
<TOTAL-REVENUES>                                 7,170
<CGS>                                                0
<TOTAL-COSTS>                                   12,346
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 139
<INCOME-PRETAX>                                (5,176)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            (5,176)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (5,176)
<EPS-BASIC>                                     (0.21)
<EPS-DILUTED>                                   (0.21)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission